Invivyd Inc. Announces Upcoming FDA Meeting in Early Q3 to Discuss Regulatory Pathways for VYD2311 COVID-19 Monoclonal Antibodies

Reuters
26 Jun
Invivyd Inc. Announces Upcoming FDA Meeting in Early Q3 to Discuss Regulatory Pathways for VYD2311 COVID-19 Monoclonal Antibodies

Invivyd, Inc. (Nasdaq: IVVD) has announced that a Type C meeting is scheduled with the FDA for early in the third quarter of 2025 to discuss the registration-directed next steps for its VYD2311 program, a next-generation monoclonal antibody candidate designed to prevent and treat COVID-19. This meeting will focus on the approval pathways for VYD2311 and other follow-on COVID-19 monoclonal antibodies, with particular attention to treatment options for active COVID-19 and prophylaxis for vulnerable populations, including the elderly, immunocompromised individuals, and pediatric populations. Invivyd plans to release additional information about the VYD2311 program throughout 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9484884-en) on June 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10